MHMichael Hejna

Michael Hejna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Hejna has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers

    by M. Kieler, A. Warzecha, L. Müllauer, F. Waneck, R. Mader, F. Wrba, M. Schmidinger, W. Scheithauer, C. Marosi, M. Raderer, et al.

  • 447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial

    by G. Prager, M. Unseld, F. Waneck, M. Raderer, M. Krainer, T. Fuereder, M. Hejna, P. Staber, W. Scheithauer, M. Schmidinger, et al.

  • Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract

    by Michael Hejna, Peter Birner, Matthias Preusser, Christiane M. R. Thallinger, Nina Worel, Reza Asari, Werner Dolak, Rainer Schmid, Sebastian F. Schoppmann, Markus Raderer

    The assessment of the human epidermal growth factor receptor-2 (HER-2) status has become a routine diagnostic procedure for patients with advanced-stage gastroesophageal adenocarcinoma. The aim of this study was to evaluate the possible correlation between the HER-2 status and the ABO blood group. HER-2 status determination and routine ABO typing was performed according to current standards. We evaluated the correlation between the HER-2 status and the ABO and Rhesus (Rh) system in 100 consecutive patients with adenocarcinoma of the upper gastrointestinal tract. There were no significant differences between HER-2 status and ABO and Rh system. Furthermore, no correlation was observed between the HER-2 status and the ABO and Rh type in patients with adenocarcinoma of the upper gastrointestinal tract.


  • Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy

    by Christiane Maria Rosina Thallinger, Markus Raderer, Michael Hejna

    The objective of this article was to review clinical trials that used antineoplastic second-line chemotherapy and/or targeted therapies in patients with esophageal cancer after first-line therapy. Computerized (MEDLINE) and manual searches were performed to identify articles published on this topic between 1996 and 2011. Twenty-five published trials and four abstracts presented at scientific meetings were identified. A total of 10 trials included only patients with squamous cell carcinomas (SCCs), four focused exclusively on adenocarcinoma (AC), the remaining 15 studies included both SCC and AC. The majority of trials (17 of 29) used docetaxel in combination with platinum analogs, eight used single-agent cytotoxic chemotherapy, and six evaluated targeted therapies. The numbers of patients were relatively small, ranging from eight to 55 patients. The response rates were generally low (between 0% and 39%), with only two small studies reporting objective responses of 50% and 63%, respectively. Time to progression ranged from 1.4 to 6.2 months, and the overall survival was disappointing at 4.0 to 11.4 months. Approximately 40% of patients who experience progressive disease after first-line chemotherapy are able to undergo second-line treatment. On the basis of data published so far, no standard second-line therapy has emerged. Future research will need to focus on individual therapy strategies such as genetic receptor mutations to increase the therapeutic outcome.


  • Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX).

    by U. Pluschnig, J. Zacherl, S. Schoppmann, M. Raderer, G. Prager, R. Bartsch, A. Ba-Ssalamah, W. Lamm, C. Zielinski, M. Hejna

    136 Background: Gastric cancer is a worldwide common malignant disease with a high mortality rate. Adjuvant chemotherapy did not result in a survival advantage in Caucasian populations. Therapeutic chemotherapy options consist of either monotherapy or of polychemotherapy and have been applied as neoadjuvant chemotherapy with combinations of epirubicin, cyclophosphamide and 5-fluorouracil or capecitabine as well as cisplatin or oxaliplatin. The aim of this retrospective analysis was to investigate the use of the EOX regimen in the neoadjuvant setting which had shown activity in advanced gastric cancer. Methods: 23 patients (pts) (median age: 70, range 36-85, years; 16 pts >65 years) with locally advanced adenocarcinoma of the upper GI-tract received 3 courses of preoperative chemotherapy with epirubicin 50 mg/m2, day1, oxaliplatin 130 mg/m2, day 1, and capecitabine 2,000 mg/m2, days 1-14, of a 3-week cycle. Toxicity was assessed by CTC (Common Toxicity Criteria) after every cycle. Progression free survival (PFS) was defined as time from surgery to disease progression assessed by PET-CT which was performed at diagnosis and after 3 cycles chemotherapy. Results: 20 pts completed all three planned cycles of preoperative chemotherapy, 2 pts received only 1 cycle because of rapid tumor progression and 1 pt. is currently still on treatment. 16 pts. underwent surgery with curative resection with 2 pCRs on pathological review. 6 pts. remained inoperable despite chemotherapy and 1 pt is currently scheduled for surgery. After surgery, 2 pts. died after a median of 9 months (8-10). 4 pts. died without surgery due to disease progression. After a median follow-up of eight months (range 5-26), median PFS and overall survival was not reached yet. In 2 pts., grade 3-4 toxicities including nausea, diarrhea and hand-foot syndrome and one non-life-threatening pulmonary embolism occurred. Conclusions: In summary, EOX is a well tolerated, safe, and efficacious neoadjuvant treatment in also elderly patients with locally advanced adenocarcinoma of the upper GI-tract. However, more studies with a larger population are needed to corroborate the current results of this promising treatment schedule. [Table: see text]

  • Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis.

    by U. Pluschnig, J. Zacherl, S. Schoppmann, M. Raderer, G. Prager, R. Bartsch, A. Ba-Ssalamah, W. Lamm, C. Zielinski, M. Hejna

    E14682 Background: Gastric cancer carries a poor prognosis and is one of the leading causes of cancer deaths worldwide. Adjuvant chemotherapy did not result in a survival advantage in Caucasian populations. Thus, other therapeutic options including perioperative chemotherapy were investigated: In the neoadjuvant setting, combinations of epirubicin, cyclophosphamide and fluorouracile or capecitabine as well as cisplatin or oxaliplatin improved outcome versus surgery alone. Here, we report on the use of the EOX regimen in the neoadjuvant setting which had shown a trend in advanced gastric cancer of superior survival outcome. Methods: 20 Patients (median age: 70.5, range 36-85, years; 15 pts > 65 years) with locally advanced adenocarcinoma of the upper GI-tract received 3 courses of perioperative chemotherapy with epirubicin 50 mg/m2, day1, oxaliplatin 130 mg/m2, day 1, and capecitabine 2,000 mg/m2, days 1- 14, of a 3-week cycle. Toxicity was assessed by CTC (Common Toxicity Criteria) for every cycle. Progression free survival (PFS) was defined as interval from surgery to disease progression assessed by PET-CT which was performed at diagnosis and after 3 cycles of chemotherapy and every twelve weeks thereafter. Results: 17 pts completed all three planned cycles of chemotherapy, 2 pts received only one cycle due to rapid tumor progression, 1 patient is currently still on treatment. 11 pts underwent surgery with curative resection with 2 pCRs. 4 pts remained inoperable despite chemotherapy and 3 pts are waiting for surgery. 1 patient died after front-line chemotherapy due to rapid tumor progression. After surgery, 3 pts died after a median of 6.8 (range: 5-8) months. Only 2 pts experienced grade 3-4 toxicities including nausea, diarrhea and hand-foot syndrome and one non-life-threatening pulmonary embolism. Dose reduction of capecitabine to 75% due to toxicity was necessary in 2 pts. PFS was 8.7 month (5.3-12.1 95%CI); overall survival is not reached, yet. Conclusions: We conclude that EOX is a well tolerated, safe, and efficacious as neoadjuvant treatment in elderly patients with locally advanced adenocarcinoma of the upper GI-tract encouraging further investigation.

  • Temporary Placement of Self-Expanding Oesophageal Stents as Bridging for Neo-Adjuvant Therapy

    by Felix B. Langer, Sebastian F. Schoppmann, Gerhard Prager, Florian Tomaselli, Ursula Pluschnig, Michael Hejna, Rainer Schmid, Johannes Zacherl

    Placement of self-expanding stents is an effective palliation for dysphagia in non-resectable oesophageal or proximal gastric cancer. The aim of this analysis was to assess the efficacy of temporary stent placement for dysphagia relief during neo-adjuvant treatment for locally advanced disease. A total of 38 patients scheduled for neo-adjuvant chemo(radio)therapy for locally advanced oesophageal cancer (n = 29), cardia cancer (n = 8) or subcardial gastric cancer (n = 1) underwent placement of self-expanding plastic stents (n = 13) or covered metal stents (n = 25) due to severe dysphagia and weight loss. Instant dysphagia relief was achieved in 37 (97.4%) of 38 patients. Dysphagia scores declined from mean 3.0 ± 0.7 before stent placement to 0.6 ± 0.9 at restaging. After completion of the neo-adjuvant therapy 20 (52.6%) of the 38 patients underwent resection of the tumour, 5 patients (13.2%) underwent primary resection without receiving chemotherapy while 12 patients (31.6%) did not undergo surgery. Stent-related complications were observed as perforation (n = 1), mediastinitis (n = 1), tracheo-oesophageal fistula (n = 2), bleeding (n = 1) and jejunal perforation caused by a migrated stent (n = 1). Serum albumin significantly decreased in patients with progressive disease despite successful stenting (40.0 ± 4.9 mg/dl versus 29.7 ± 6.4 mg/dl, p < 0.05) while stable albumin levels were found in patients who underwent surgery (39.9 ± 4.3 mg/dl versus 39.1 ± 3.8 mg/dl, p = 0.484). Placement of self-expanding stents is highly effective for instant dysphagia relief, enabling adequate oral nutrition during neo-adjuvant therapy, but is limited by a high re-intervention rate.


  • Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001

    by Michael Hejna, Markus Raderer, Johannes Zacherl, Ahmed Ba-Ssalamah, Andreas Püspök, Manuela Schmidinger, Ursula Pluschnig, Thomas Brodowicz, Christoph C. Zielinski

    A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/m2 and oxaliplatin 100 mg/m2 both infused on day 1. A prophylactic 5-day course of human granulocyte colony-stimulating factor 5 μg/kg/day was given subcutaneously, and erythropoietin (10 000 IU subcutaneously three times per week) was administered if hemoglobin was less than 12.0 mg/dl. The confirmed overall response rate was 34%, including two complete responses (6%) and 10 partial responses (28%). Fifteen patients (43%) had stable disease. The median time to response was 2.5 months (1–3.5), the median time to progression was 8.9 (4–42.5) months and the median overall survival time was 11.6 (2.5–51) months. Hematologic toxicity was common, though World Health Organization grade 3 or 4 neutropenia occurred only in six (17%) patients and anemia in six (17%) patients, respectively. Nonhematologic adverse reactions were usually mild-to-moderate. Our data suggest that the combination of docetaxel and oxaliplatin with granulocyte colony-stimulating factor and erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal adenocarcinoma.


  • Postoperative Chemotherapy for Gastric Cancer

    by Michael Hejna, Stefan Wöhrer, Manuela Schmidinger, Markus Raderer

    Introduction. Adjuvant chemotherapy for gastric cancer after potentially curative surgery has been under clinical investigation for more than four decades. However, potentially curative resection can be performed in only 30%–50% of patients. The objective of this article is to review briefly the clinical trials available in the current literature using adjuvant cytotoxic chemotherapy in patients with gastric cancer after potentially curative surgical resection. Methods. Computerized (MEDLINE) and manual searches were performed to identify papers published on this topic between 1965 and 2005. Only articles with an English abstract were reviewed for inclusion; information abstracted included histologic proof of diagnosis, number of patients, dose and modality of treatment, survival duration, and side effects. Results. Forty-three reports were identified. Single-agent chemotherapy was evaluated in four clinical trials, and postoperative combination chemotherapy was evaluated in 33 trials. Furthermore, we identified five meta-analyses. Five-year survival rates ranged from 12%–91.2%, and the median survival durations were 13–60+ months. Adjuvant chemotherapy, when compared with surgery alone, seems to result in longer survival. Conclusion. The high rate of recurrence, even in patients undergoing state-of-the art curative resection, suggests that effective adjuvant chemotherapy might indeed be an attractive concept to improve the overall outcome of patients with gastric cancer. However, because there is no standard regimen for postoperative treatment at the moment, patients with R0-resected (no residual tumors) gastric cancer should be offered the opportunity to participate in prospective clinical trials.